Crossmark

An open-source clinical bioinformatics pipeline for real-world NGS implementation: translating genomic variants into actionable treatment strategies in oncology

Crossref DOI link: https://doi.org/10.1186/s12967-026-07718-w

Published Online: 2026-01-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Privitera, Grete Francesca

Alaimo, Salvatore

Micale, Giovanni

Giaimi, Luca

Mare, Marzia

Lombardo, Sofia Paola

Martorana, Emanuele

Villa, Riccardo

Ferro, Alfredo

Forte, Stefano

Pulvirenti, Alfredo https://orcid.org/0000-0002-9764-0295
License Information

Text and Data Mining valid from 2026-01-21

Version of Record valid from 2026-02-13
More Information

Article History

Received: 30 September 2025

Accepted: 31 December 2025

First Online: 21 January 2026

Declarations

:

: The study is conducted in accordance with the Declaration of Helsinky, complied with national ethical guidelines and was approved by the Ethical Committee “Catania 2” under protocol number 116, dated February 22, 2022. Written informed consent was obtained from all participating patients.

: The authors declare that a patent regarding the primary technology described in the manuscript has been granted (Italian Patent Office, patent number: 102,023,000,012,882 of 16/06/2025). All authors declare no other financial or non-financial competing interests.

Document is current

Any future updates will be listed below